Vebreltinib yemerewe mu Bushinwa gukoresha MET-Amplified NSCLC

Ku ya 30 Kamena, umuti wa Avistone wo mu bwoko bwa Vebreltinib wakozwe ku giti cye wahawe uburenganzira bwo kuvura abarwayi bafite kanseri y’ibihaha idakomeye cyangwa isanzwe (NSCLC) ifite ubushobozi bwo kongera ingufu za MET. Iki ni ikimenyetso cya gatatu cyemewe cya Vebreltinib mu Bushinwa, kikaba ari na cyo cya mbere ku isi cyemewe ku barwayi ba NSCLC bafite ubushobozi bwo kongera ingufu za MET.

Kwemezwa kwa Vebreltinib mu Bushinwa kuri iki kimenyetso gishya—kuvura abarwayi barwaye kanseri y’ibihaha idateye imbere cyangwa isanzwe (NSCLC) ifite MET amplification—byashingiye ku bisubizo byiza byavuye mu bushakashatsi bwa KUNPENG bwakozwe na Cohort 2 na Cohort 3 (NCT04258033) ku barwayi.

Itsinda rya 2 ryigaga cyane cyane abarwayi bari baravuwe mbere bafite NSCLC ya MET yananiwe kuvurwa neza (harimo na platine-based chemotherapy), mu gihe Itsinda rya 3 ryigaga cyane cyane abarwayi batari basanzwe bafite NSCLC ya MET ya NET yanze chemotherapy.

Abarwayi 86 bafite NSCLC yateye imbere cyangwa yanduye mu gace runaka biyandikishije mu matsinda yombi (33 mu itsinda rya 2 na 53 mu itsinda rya 3). Ibisubizo by'ubushakashatsi byagaragaje igipimo rusange cy'ubutabazi (ORR) cya 48.8%, igipimo cyo kurwanya indwara (DCR) cya 77.9%, igihe cyo gusubiza (DoR) cy'amezi 12.1, igihe cyo kubaho kidashingiye ku iterambere (PFS) cy'amezi 7.4, n'igihe cyo kubaho kidashingiye ku iterambere (OS) cy'amezi 13.9.

Mu itsinda rya 2 (abarwayi 33 bavuwe mbere), ORR yari 48.5%, DCR yari 78.8%, DoR yari 11.0%, PFS yari 6.2%, naho OS yari 11.7%.

Mu itsinda rya 3 (abarwayi 53 batavuwe neza), ORR yari 49.1%, DCR yari 77.4%, DoR yari 12.1%, PFS yari 8.3%, naho OS yari 15.5%.

Mu bushakashatsi bwa KUNPENG, abarwayi 21 bafite indwara ya metastases yo mu bwonko bw’ibanze basuzumwe na Komite Yigenga Isuzuma (IRC). Muri abo, 10 babonye ibisubizo byemewe by’igice (PR), bituma ORR ya 47.6%, DCR ya 85.7%, na DoR y’ikigereranyo cy’amezi 11.0. Byongeye kandi, PFS y’ikigereranyo na OS byari amezi 8.3 n’amezi 14.7, uko bikurikirana.

Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.

Nimero ya Terefone: 4008803716

Email：myimmnet@163.com